I'm LongbridgeAI, I can summarize articles.INNOCARE (09969.HK) +0.550 (+4.816%) Short selling $9.10M; Ratio 23.152% last traded at HKD12 this afternoon (28th), up 5.08%, with turnover of 3.9105 million shares, involving HKD46.2855 million.
Goldman Sachs said in a research report that INNOCARE's drug sales in 3Q26 reached RMB531 million, up 39% YoY and broadly in line with the broker's forecast of RMB548 million. The growth was mainly driven by continued volume expansion of orelabrutinib, including contributions after first-line CLL/SLL was included in the National Reimbursement Drug List, as well as differentiated contributions from MZL. Total revenue reached RMB962 million, up 150% YoY and above the broker's expectations, mainly due to milestone income from the Zenas collaboration, supporting net profit of RMB409 million in the third quarter.
Management maintained guidance for drug sales growth of more than 35% in 2026 and expects profitability to remain sustainable. Excluding BD income, management said the core commercial business could achieve standalone break-even when drug sales reach around RMB2.5 billion to RMB3 billion. The broker forecasts 2026 drug sales at RMB2 billion, while recurring potential BD income may provide additional upside to earnings forecasts. The broker also noted that multiple late-stage projects are approaching commercialization, while the early-stage pipeline is expanding into ADCs and novel immunological mechanisms. Its cooperation with Eli Lilly also provides external validation for its small-molecule discovery capabilities.
Following the results, the broker raised its 2026-2028 net profit forecasts by RMB447 million, RMB108 million and RMB17 million respectively, mainly reflecting better-than-expected collaboration income, while drug sales forecasts were largely unchanged. The broker raised the 12-month H-share TP to HKD23.16 from HKD22.71, and increased the A-share TP for INNOCARE (688428.SH) +0.320 (+1.272%) to RMB38.68 from RMB37.93, with a Buy rating maintained. (ad/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-10-28 12:25.) (A Shares quote is delayed for at least 15 mins.)
